Mutagenicity studies with N6, O2'-dibutyryl cyclic adenosine 3',5'-monophosphate (DBcAMP).
N6,O2'-Dibutyryl cyclic adenosine 3,5-monophosphate (DBcAMP) was studied for mutagenicity using the rec assay, the Ames method, and in vitro cytogenetics. DBcAMP had no mutagenic effect on B. subtilis in the rec assay, or on S. typhimurium (TA1535, TA1537, TA1538, TA98 and TA100) or E. coli (WP2 uvrA). In the cytogenetic study, a significant increase in chromosomal aberrations was observed at a concentration of 50,000 micrograms/ml, but it was considered that this effect could be attributed to the secondary effect of the high osmotic pressure in the culture medium. These results suggest that DBcAMP has no mutagenic potential.
Shimada
H
H
Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.
Ebine
Y
Y
D000818:Animals; D001412:Bacillus subtilis / Q000187:drug effects; D003994:Bucladesine / Q000633:toxicity*; D002460:Cell Line; D002869:Chromosome Aberrations; D006224:Cricetinae; D009152:Mutagenicity Tests; D009154:Mutation / Q000187:drug effects*; D009994:Osmolar Concentration; D011938:Rec A Recombinases / Q000502:physiology; D011995:Recombination, Genetic / Q000187:drug effects; D012486:Salmonella typhimurium / Q000187:drug effects
D003994:Bucladesine; D011938:Rec A Recombinases